Clinical Trial Update: Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the immunogenicity of the Human Rotavirus Vaccine after reconstitution without a buffering agent. It also evaluates immunogenicity, reac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Gastroenteritis

Drugs mentioned

• Rotarix (Rotavirus vaccine (live attenuated))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rotavirus Gastroenteritis | Phase 3 | Status: COMPLETED